Evidence map›Paper›PMID 34778969›Full record

ArticleFEBS letters2022

The mitochondrial regulator PGC1α is induced by cGMP-PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure.

Guangshuo Zhu, Kazutaka Ueda, Masaki Hashimoto, Manling Zhang, Masayuki Sasaki, Taro Kariya, Hideyuki Sasaki, Nina Kaludercic, Dong-Ik Lee, Djahida Bedja and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome.Journal of cardiovascular development and disease · 2022
    Article
  11. Cyclic GMP and PKG Signaling in Heart Failure.Frontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Guangshuo ZhuDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kazutaka UedaDepartment of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Masaki HashimotoDepartment of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0002-4340-3358
Manling ZhangDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Masayuki SasakiDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Taro KariyaDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hideyuki SasakiDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nina KaludercicDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dong-Ik LeeDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Djahida BedjaDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Matthew GabrielsonDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yuan YuanDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nazareno PaolocciDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert M BlantonMolecular Cardiology Research Institute and Division of Cardiology, Tufts Medical Center, Boston, MA, USA.
Richard H KarasMolecular Cardiology Research Institute and Division of Cardiology, Tufts Medical Center, Boston, MA, USA.
Michael E MendelsohnMolecular Cardiology Research Institute and Division of Cardiology, Tufts Medical Center, Boston, MA, USA.
Brian O'RourkeDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David A KassDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-1596-2299
Eiki TakimotoDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-7767-0094
Johns Hopkins University · USTufts Medical Center · USThe University of Tokyo · JP

Funding

Leveraging Protein Kinase G-1 Nanodomain Control and Molecular Targeting to Enhance its Therapeutic Use Against Myocardial DiseaseR35HL135827 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KASS, DAVID ALAN · 2017 to 2023
$6.3M
Regulation and function of cGMP dependent protein kinase in cardiac hypertrophyR01HL093432 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TAKIMOTO, EIKI · 2009 to 2013
$2.3M
Targeting Metabo-Redox Network Vulnerability in Heart Failure and Sudden DeathR01HL134821 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI FOSTER, D BRIAN, O'ROURKE, BRIAN · 2018 to 2021
$2.1M
Novel Protein Kinase GI Substrates in Cardiac Remodeling and Blood Pressure ControlR01HL131831 · NHLBI · TUFTS MEDICAL CENTER · PI BLANTON, ROBERT MORRIS · 2016 to 2020
$2.1M
Regulation of Cardiac Stress Responses by PDE5aR01HL089297 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KASS, DAVID ALAN · 2008 to 2011
$1.8M
NHLBI NIH HHS R01 HL089297NHLBI NIH HHS R01 HL093432NHLBI NIH HHS R01 HL131831NHLBI NIH HHS R01 HL134821NHLBI NIH HHS R35 HL135827
6 · The paper itself

Abstract

Phosphodiesterase 5 inhibition (PDE5i) activates cGMP-dependent protein kinase (PKG) and ameliorates heart failure; however, its impact on cardiac mitochondrial regulation has not been fully determined. Here, we investigated the role of the mitochondrial regulator peroxisome proliferator-activated receptor γ co-activator-1α (PGC1α) in the PDE5i-conferred cardioprotection, utilizing PGC1α null mice. In PGC1α

Indexed as

Cyclic GMPCyclic GMP-Dependent Protein KinasesHeart FailurePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPhosphodiesterase 5 InhibitorsSignal TransductionSildenafil CitrateAnimalsCyclic AMP Response Element-Binding ProteinMaleMiceMice, Inbred C57BLMice, KnockoutMitochondriaMitochondria, HeartMyocytes, CardiacCyclic AMP Response Element-Binding ProteinCyclic GMPCyclic GMP-Dependent Protein KinasesPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPhosphodiesterase 5 InhibitorsPpargc1a protein, mouseSildenafil Citratecyclic guanosine monophosphateheart failuremitochondriaPGC1α

Identifiers

PMID34778969
PMCPMC9199229
OpenAlexW3211782457

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.